Living Cell Technologies Ltd
ASX:LCT

Watchlist Manager
Living Cell Technologies Ltd Logo
Living Cell Technologies Ltd
ASX:LCT
Watchlist
Price: 0.012 AUD
Market Cap: AU$19.6m

Net Margin

-5 015.8%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-5 015.8%
=
Net Income
AU$-2.1m
/
Revenue
AU$42k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-5 015.8%
=
Net Income
AU$-2.1m
/
Revenue
AU$42k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Living Cell Technologies Ltd
ASX:LCT
18.7m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 87% of companies in Australia
Percentile
13th
Based on 4 004 companies
13th percentile
-5 015.8%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Living Cell Technologies Ltd
Glance View

Market Cap
19.6m AUD
Industry
Biotechnology

Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The firm's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. The company has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.

LCT Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-5 015.8%
=
Net Income
AU$-2.1m
/
Revenue
AU$42k
What is Living Cell Technologies Ltd's current Net Margin?

The current Net Margin for Living Cell Technologies Ltd is -5 015.8%, which is in line with its 3-year median of -5 015.8%.

How has Net Margin changed over time?

Over the last 2 years, Living Cell Technologies Ltd’s Net Margin has decreased from -544.6% to -5 015.8%. During this period, it reached a low of -57 398.8% on Jun 30, 2022 and a high of -544.6% on May 30, 2021.

Back to Top